Skip to main content

About Marcio Fagundes


Marcio Fagundes, M.D., is the Medical Director of the Radiation Oncology Department of the Miami Cancer Institute at Baptist Health South Florida. Dr. Fagundes attended medical school at Universidad Federal do Rio Grande do Sul in Brazil. He completed internship at Jackson Memorial Hospital, residency in radiation oncology at Sylvester Comprehensive Cancer Center and fellowship in radiation oncology (proton therapy) at Massachusetts General Hospital, Harvard dedicated to proton therapy training. Following fellowship, Dr. Fagundes served as assistant professor of radiation oncology at TUFTS University School of Medicine in Boston, during which time intensity modulated radiotherapy was being developed into clinical use. Dr. Fagundes worked for several years in Brazil where he introduced several advances in radiotherapy such as radiosurgery, high dose rate brachytherapy for gynecologic and breast malignancies, as well as low dose rate permanent implant brachytherapy for prostate cancer.

During the 5 years that preceded joining Baptist Health South Florida, he developed extensive experience in proton therapy practicing full time first at the Procure Oklahoma City Proton Center as staff physician for 2 years. He subsequently led the opening of the Provision Proton Center in Knoxville as Medical Director, TN where he practiced between 2013-2016. Dr. Fagundes has conducted significant research in the field of proton therapy, including innovative applications such as proton therapy for breast cancer and hypofractionated proton therapy for prostate cancer. Dr. Fagundes led the efforts to introduce pencil beam scanning proton therapy in Knoxville in replacement of the older method called uniform scanning. Pencil beam scanning proton therapy also known as spot scanning technique allows even better control of dose deposition of conformal dose around the target while sparing normal organs, having the advantage of treating larger fields like pelvic lymph nodes.

Dr. Fagundes pioneered the utilization of rectal spacer gel known as SpaceOAR to displace the rectum away from the prostate being the first physician to utilize this method with proton therapy in the world on April 6th 2015, following the FDA release of SpaceOAR rectal spacer. He has treated well over 300 prostate cancer patients with rectal spacer and proton therapy exceptional outcomes presented in multiple worldwide medical meetings such as PTCOG – Proton Therapy Collaborative Group. Dr. Fagundes is a mentor and trains physicians who are in the process of adopting these new techniques, including various forms of advanced proton therapy.

Following inauguration of the new Miami Cancer Institute in February of 2017, Dr. Fagundes leads the efforts in proton therapy implementation as Medical Director of the Miami Cancer Institute Radiation Oncology Department as part of Baptist Health South Florida since October 2016. This facility is unique worldwide having available all modalities of radiotherapy including Linac based IMRT - Intensity Modulated Radiotherapy, Tomotherapy, Cyberknife, Gamma knife, MRLinac and proton therapy. This facility can effectively perform comparative plan and offer patients the best modality for each scenario having no preconceived preference occasionally driven by technique availability or resource limitations.

Positions

2016 - Present Radiation Oncologist, Baptist Health South Florida ‐ Miami Cancer Institute
to
2013 - 2016 Medical Director Provision Center for Proton Therapy, Radiation Oncology, Knoxville, TN, Provision Center for Proton Therapy
to
2011 - 2013 Medical Staff, ProCure Oklahoma City Proton Therapy Center ‐ Oklahoma Proton Radiation Therapy Group
to
2007 - 2011 Medical Staff, Missouri Baptist Medical Center
to
1996 - 2007 Medical Director, Radioterapica do RGS, Porto Alegre, Brazil
to

Disciplines

Research Interests

Grants

2016 - Present Pragmatic Phase III Randomized Trial of Proton vs Photon Therapy for Patients with non-metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RACOMP)
Abramson Cancer Center of the University of Pennsylvania - NCT02603341
Role: Site Contact. Miami Cancer Institute
2014 - Present A Phase II Study of Hypofractionated Image Guided Proton Therapy for Low and Intermediate Risk Prostate Cancer
Provision Center for Proton Therapy - NCT02040610
2014 - Present Randomized Phase II Trial of Hypofracionated Dose-Escalation Photon IMRT or Proton Beam Therapy vs Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
NRG Oncology - NCT02179086
Role: Sub-Investigator
2012 - Present Prostate Advanced Radiation Technologies Investigating Quality of Life PARTIQoL: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Massachusetts General Hospital - NCT01617161
Role: Co-Principal Investigator
2010 - 2020 Retreatment of Recurrent Tumors Using Proton Therapy
Abramson Cancer Center of the University of Pennsylvania - NCT01126476
Retreatment of Recurrent Tumors Using Proton Therapy
Role: Site Principal Investigator, ProCure, Oklahoma City, OK
2012 - 2018 RTOG 1205: Randomized Phase II Trial of Concurrent Bevazizumab and Re-irradiation vs Bevacizumab alone as treatment for Recurrent Glioblastoma (open to accrual at Provision Proton Center
Radiation Therapy Oncology Group - NCT01730950
Role: Sub-Investigator
2009 - 2017 A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Resectable Carcinoma of the Pancreas
University of Florida - NCT00763516
Role: Sub-Investigator, Institutional PI
2013 - 2016 A Phase II Trial of Postoperative Proton Therapy with Concurrent Chemotherapy for Patients with Resected Pancreatic Adenocarcinoma
Provision Proton Center
Role: Sub-Investigator, Institutional PI
2013 - 2016 Multi-Institutional Registry and Treatment Outcomes Trial
Provision Center for Proton Therapy
Role: Role: Principal Investigator, between opening to accrual
$
to
Enter a valid date range.

Professional Service and Affiliations

2013 - Present Member, Particle Therapy Cooperative Group - North America (PTCOG-NA)
1994 - Present Member, American Society for Therapeutic Radiology and Oncology (ASTRO)
to
Enter a valid date range.

Courses

  • 2019 - Present Associate Professor FIU Herbert Wertheim College of Medicine 1994
  • 1994-1996 Assistant Professor in Radiation Oncology TUFTS University New England Medi

Education

to
1993 - 1994 Clinical Fellowship, Radiation Oncology, Harvard School of Medicine, Massachusetts General Hospital, Boston, MA
to
1990 - 1993 Residency, Radiation Oncology, University of Miami, Jackson Memorial Hospital/Sylvester Cancer Center, Miami, FL
to
1989 - 1990 Internship, General Medicine, University of Miami, Jackson Memorial Hospital, Miami, FL
to
1988 - 1989 Clinical volunteer clerkship, Radiation Oncology, Centro de Oncologia Radioterapica do RGS, Brazil
to
1982 - 1988 Doctor of Medicine, Universidade Federal do RGS, Porto Alegre, Brazil
to

Links

Contact Information

Miami Cancer Institute
8900 N. Kendall Drive
Miami, FL 33176
(786) 596-2000

Articles (49)